List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7878271/publications.pdf Version: 2024-02-01



RIN S TEH

#	Article	IF	CITATIONS
1	Neoadjuvant Chemotherapy for Metaplastic Breast Cancer: Response Rates, Management, and Outcomes. Clinical Breast Cancer, 2022, 22, e691-e699.	1.1	13
2	Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma. Journal of Neuro-Oncology, 2022, 157, 137-146.	1.4	8
3	Contemporary trends in management of uveal melanoma. Journal of Contemporary Brachytherapy, 2022, 14, 123-129.	0.4	1
4	Abstract P3-19-15: Prognostic impact of radiation therapy in mucinous carcinoma of the breast. Cancer Research, 2022, 82, P3-19-15-P3-19-15.	0.4	0
5	Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncológica, 2022, 61, 403-408.	0.8	6
6	Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques. Journal of Contemporary Brachytherapy, 2022, 14, 130-139.	0.4	2
7	Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases. Breast Cancer Research and Treatment, 2022, 193, 613-623.	1.1	1
8	A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. Future Oncology, 2022, 18, 2771-2781.	1.1	2
9	A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer (RAD VACCINE MIBC) Journal of Clinical Oncology, 2022, 40, TPS4611-TPS4611.	0.8	0
10	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print]. European Urology Focus. 2021. 7, 404-405	1.6	3
11	Management, outcomes, and prognostic factors of adult primary spinal cord gliomas. Journal of Clinical Neuroscience, 2021, 84, 8-14.	0.8	6
12	Staged Stereotactic Radiosurgery Decreases Symptomatic Radionecrosis in Large Brain Metastasis. Anticancer Research, 2021, 41, 1445-1449.	0.5	2
13	Chordoma—Current Understanding and Modern Treatment Paradigms. Journal of Clinical Medicine, 2021, 10, 1054.	1.0	37
14	Outcomes following stereotactic radiosurgery or whole brain radiation therapy by molecular subtype of metastatic breast cancer. Reports of Practical Oncology and Radiotherapy, 2021, 26, 341-351.	0.3	4
15	Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. Journal of Clinical Neuroscience, 2021, 85, 115-121.	0.8	9
16	The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast. Reports of Practical Oncology and Radiotherapy, 2021, 26, 179-187.	0.3	3
17	A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP) Journal of Clinical Oncology, 2021, 39, 1079-1079.	0.8	6
18	Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer Journal of Clinical Oncology, 2021, 39, 9115-9115.	0.8	4

#	Article	IF	CITATIONS
19	Role of 21- gene recurrence score in patients age ≥70 with T1N0 ER/PR+ HER2- breast cancer treated with breast-conserving surgery and endocrine therapy Journal of Clinical Oncology, 2021, 39, 571-571.	0.8	0
20	Adaptive Radiation Therapy for Intact Thymoma: An Illustrative Report. Anticancer Research, 2021, 41, 2467-2471.	0.5	1
21	Prognostic impact of radiation therapy in tubular carcinoma of the breast. Radiotherapy and Oncology, 2021, 159, 202-208.	0.3	7
22	Staged Eye-Plaque Brachytherapy: A Novel Approach for Large Uveal Melanoma. Advances in Radiation Oncology, 2021, 6, 100712.	0.6	1
23	Solitary Leptomeningeal Recurrence From Prostate Adenocarcinoma After Treatment With Cytotoxic Gene Therapy, Radiation Therapy, and Androgen Deprivation Therapy. Advances in Radiation Oncology, 2021, 6, 100711.	0.6	0
24	Postmastectomy radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy: A prelude to NSABP B-51?. Radiotherapy and Oncology, 2021, 162, 52-59.	0.3	7
25	Time Interval to Initiation of Whole-Brain Radiation Therapy in Patients With Small Cell Lung Cancer With Brain Metastasis. Advances in Radiation Oncology, 2021, 6, 100783.	0.6	3
26	Comparison of Survival Outcomes With/Without Adjuvant Radiation Therapy in Desmoplastic Melanoma. Dermatologic Surgery, 2021, 47, 1333-1336.	0.4	1
27	Comparison of outcomes between metaplastic and triple-negative breast cancer patients. Breast, 2020, 49, 8-16.	0.9	32
28	Clinical presentation, national practice patterns, and outcomes of breast adenomyoepithelioma. Breast Journal, 2020, 26, 653-660.	0.4	19
29	31. RADIATION NECROSIS IN STEREOTACTIC RADIOSURGERY AND CHECKPOINTS INHIBITORS FOR BRAIN METASTASES FROM LUNG ADENOCARCINOMA. Neuro-Oncology Advances, 2020, 2, ii5-ii5.	0.4	0
30	Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093615.	1.4	17
31	Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. Journal of Contemporary Brachytherapy, 2020, 12, 303-310.	0.4	7
32	Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 2419-2427.	0.6	0
33	Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). International Journal of Radiation Oncology Biology Physics, 2020, 108, 941-949.	0.4	48
34	Patterns of management and outcomes of unifocal versus multifocal glioblastoma. Journal of Clinical Neuroscience, 2020, 74, 155-159.	0.8	20
35	Prognostic role of chemotherapy, radiotherapy dose, and extent of surgical resection in adult medulloblastoma. Journal of Clinical Neuroscience, 2020, 76, 154-160.	0.8	4
36	The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast. Breast Journal, 2019, 25, 1171-1176.	0.4	19

#	Article	IF	CITATIONS
37	Short-term Mortality Associated with Definitive Chemoradiotherapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e1069-e1079.	0.9	8
38	The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Focus, 2019, 5, 958-969.	1.6	86
39	Omission of radiation therapy following breast conservation in older (≥70 years) women with T1â€2N0 tripleâ€negative breast cancer. Breast Journal, 2019, 25, 1126-1133.	0.4	11
40	Biopsy proven metastatic meningioma: A case report and review of the literature. Reports of Practical Oncology and Radiotherapy, 2019, 24, 528-532.	0.3	5
41	Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Communications, 2019, 39, 1-9.	3.7	19
42	Socioeconomic Factors Associated with Lack of Treatment in Early Stage Non-Small Cell Lung Cancer. Cancer Investigation, 2019, 37, 506-511.	0.6	4
43	Stereotactic radiosurgery for brain metastases from newly diagnosed small cell lung cancer: practice patterns and outcomes. Acta Oncolųgica, 2019, 58, 491-498.	0.8	28
44	Disparities in the Treatment and Outcome of Stage I Non–Small-Cell Lung Cancer in the 21st Century. Clinical Lung Cancer, 2019, 20, 194-200.	1.1	22
45	ASO Author Reflections: Postoperative Radiotherapy for Patients with Mesothelioma—Past, Present, and Future. Annals of Surgical Oncology, 2019, 26, 635-636.	0.7	0
46	Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma. Acta OncolA³gica, 2019, 58, 1259-1266.	0.8	19
47	Patterns of End-of-Life Oncologic Care for Stage IV Non-small Cell Lung Cancer in the United States. Anticancer Research, 2019, 39, 3137-3140.	0.5	7
48	ASO Author Reflections: Optimal Management of Anal Adenocarcinoma: Clues from a Large, National Database. Annals of Surgical Oncology, 2019, 26, 625-625.	0.7	0
49	Cancer related fatigue in prostate cancer. Translational Andrology and Urology, 2019, 8, S106-S108.	0.6	3
50	Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report. Reports of Practical Oncology and Radiotherapy, 2019, 24, 276-280.	0.3	33
51	The Value of Surgical Exposure in Radiation Oncology Training. International Journal of Radiation Oncology Biology Physics, 2019, 103, 775.	0.4	1
52	Survival Outcomes and Patterns of Management for Anal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 1351-1357.	0.7	23
53	Reply to the letter "Pure or mixed type invasive lobular carcinoma; are they different from each other?â€ŧ Breast, 2019, 43, 151-152.	0.9	0
54	Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes. Lung Cancer, 2019, 130, 93-100.	0.9	15

#	Article	IF	CITATIONS
55	The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma. Annals of Surgical Oncology, 2019, 26, 1879-1885.	0.7	15
56	Toxicity of pelvic nodal radiation for localized prostate cancer. Annals of Translational Medicine, 2019, 7, S359-S359.	0.7	1
57	Neoadjuvant radiation therapy for esophageal cancer: is a higher dose better?. Journal of Thoracic Disease, 2019, 11, 5631-5634.	0.6	0
58	Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States. Journal of Immunotherapy, 2019, 42, 228-235.	1.2	53
59	The Role of Eye Plaque Brachytherapy and MR Imaging in the Management of Diffuse Choroidal Hemangioma: An Illustrative Case Report and Literature Review. Practical Radiation Oncology, 2019, 9, e452-e456.	1.1	3
60	Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 258-264.	0.6	3
61	Postmastectomy radiation therapy for triple negative, node-negative breast cancer. Radiotherapy and Oncology, 2019, 132, 48-54.	0.3	17
62	Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer. Lung Cancer, 2019, 127, 76-83.	0.9	7
63	Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma. Breast, 2019, 43, 67-73.	0.9	14
64	Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. Journal of Urology, 2019, 201, 1097-1104.	0.2	24
65	Community-based Disparities in the Treatment and Outcomes of Early-stage Non-small-cell Carcinoma . Cureus, 2019, 11, e5889.	0.2	0
66	Combinatorial Anatomic and Functional Neural Tract Mapping for Stereotactic Radiosurgery Planning. Cureus, 2019, 11, e6161.	0.2	1
67	Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial. Translational Cancer Research, 2019, 8, S589-S591.	0.4	1
68	The impact of comorbidity on overall survival in elderly nasopharyngeal carcinoma patients: a National Cancer Data Base analysis. Cancer Medicine, 2018, 7, 1093-1101.	1.3	21
69	Adjuvant Management of Pathologic Node–Positive Disease After Definitive Surgery for Clinical T1-2 NO Rectal Cancer. Clinical Colorectal Cancer, 2018, 17, e519-e530.	1.0	6
70	Utilization of Stereotactic Radiosurgery for Renal Cell Carcinoma Brain Metastases. Clinical Genitourinary Cancer, 2018, 16, e935-e943.	0.9	28
71	Omission of radiotherapy in elderly women with early stage metaplastic breast cancer. Breast, 2018, 38, 154-159.	0.9	20
72	Metaplastic Breast Cancer: Practice Patterns, Outcomes, and the Role of Radiotherapy. Annals of Surgical Oncology, 2018, 25, 928-936.	0.7	41

#	Article	IF	CITATIONS
73	Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer, 2018, 124, 934-942.	2.0	125
74	Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2018, 170, 559-567.	1.1	207
75	Yield, Techniques, and Complications of Transvitreal and Transscleral Biopsies in Small Uveal Melanoma. JAMA Ophthalmology, 2018, 136, 482.	1.4	26
76	Radiation Oncology in the Face of Natural Disaster: The Experience of Houston Methodist Hospital. International Journal of Radiation Oncology Biology Physics, 2018, 100, 843-844.	0.4	3
77	Renal cell carcinoma brain metastasis with pseudoprogression and radiation necrosis on nivolumab after previous treatment with stereotactic radiosurgery: An illustrative case report and review of the literature. Practical Radiation Oncology, 2018, 8, e262-e265.	1.1	8
78	Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA. Future Oncology, 2018, 14, 819-827.	1.1	15
79	Changes in Treatment Patterns and Overall Survival in Patients With Early-Stage Non–Small Cell Lung Cancer in the United States After the Incorporation of Stereotactic Ablative Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 259-266.	0.6	32
80	Prognostic Factors, Treatment, and Outcomes in Early Stage, Invasive Papillary Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 532-537.	0.6	7
81	Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival. Journal of Neuro-Oncology, 2018, 136, 307-315.	1.4	21
82	Trends in Cardiac Mortality in Patients With Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 470-477.	0.4	25
83	National Practice Patterns and Outcomes for T4b Urothelial Cancer of the Bladder. Clinical Genitourinary Cancer, 2018, 16, 42-49.e1.	0.9	17
84	Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: AÂPopulation-based Study. Clinical Breast Cancer, 2018, 18, e97-e105.	1.1	8
85	The role of adjuvant chemotherapy in locally advanced bladder cancer. Acta Oncológica, 2018, 57, 509-515.	0.8	22
86	Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base. Acta Oncológica, 2018, 57, 782-789.	0.8	11
87	Practice Patterns and Outcomes in Elderly Stage I Non–Small-cell Lung Cancer: A 2004 to 2012 SEER Analysis. Clinical Lung Cancer, 2018, 19, e269-e276.	1.1	53
88	Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States. Journal of Gastrointestinal Oncology, 2018, 9, 282-294.	0.6	11
89	Utilization of intensity modulated radiation therapy for anal cancer in the United States. Journal of Gastrointestinal Oncology, 2018, 9, 466-477.	0.6	7
90	Clinical benefit to regionalization of care for muscle invasive bladder cancer. Translational Andrology and Urology, 2018, 7, S98-S100.	0.6	1

#	Article	IF	CITATIONS
91	Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base. Journal of Gastrointestinal Oncology, 2018, 9, 80-89.	0.6	32
92	Trends and disparities in the utilization of hypofractionated neoadjuvant radiation therapy for rectal cancer in the United States. Journal of Gastrointestinal Oncology, 2018, 9, 601-609.	0.6	8
93	NCMP-08. MANAGEMENT OF RADIONECROSIS AFTER STEREOTACTIC RADIATION FOR BRAIN METASTASES IN THE SETTING OF IMMUNE CHECKPOINT INHIBITORS. Neuro-Oncology, 2018, 20, vi195-vi195.	0.6	0
94	Current Practice and Future Directions for Metaplastic Breast Cancer. Annals of Surgical Oncology, 2018, 25, 630-631.	0.7	2
95	Postoperative chemoradiotherapy versus radiotherapy alone for elderly cervical cancer patients with positive margins, lymph nodes, or parametrial invasion. Journal of Gynecologic Oncology, 2018, 29, e97.	1.0	6
96	Radiation pneumonitis in pediatric Hodgkin lymphoma patients receiving radiation therapy to the chest. Practical Radiation Oncology, 2018, 8, e364-e368.	1.1	10
97	Patterns of Care and Outcomes of Hypofractionated Chemoradiation Versus Conventionally Fractionated Chemoradiation for Glioblastoma in the Elderly Population. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 167-172.	0.6	17
98	A rare presentation of choroidal metastasis from primary esophageal adenocarcinoma successfully treated with intensity-modulated radiation therapy. American Journal of Ophthalmology Case Reports, 2018, 11, 19-22.	0.4	1
99	Cardiac mortality in limited-stage small cell lung cancer. Radiotherapy and Oncology, 2018, 128, 492-497.	0.3	10
100	The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer. Bladder Cancer, 2018, 4, 205-213.	0.2	19
101	Implications of Internal Mammary Lymph Node Sampling During Microsurgical Breast Reconstruction. Annals of Surgical Oncology, 2018, 25, 3134-3140.	0.7	4
102	Omission of chemotherapy for low-grade, luminal A N1 breast cancer: Patterns of care and clinical outcomes. Breast, 2018, 41, 67-73.	0.9	10
103	Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer. Radiotherapy and Oncology, 2018, 129, 264-269.	0.3	40
104	Longâ€term outcome of a moderately hypofractionated, intensityâ€modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer. Cancer Communications, 2018, 38, 1-9.	3.7	9
105	The long-term sequelae of palliative radiation therapy to lumbosacral spine using conventional PA-single portal technique. Practical Radiation Oncology, 2018, 8, 376-381.	1.1	0
106	The utility of PET-CT after preoperative chemoradiation in predicting treatment outcomes in locally advanced esophageal cancer Journal of Clinical Oncology, 2018, 36, 182-182.	0.8	0
107	Utilization of Hysterectomy Following Chemoradiation for IB2/IIA2 Cervical Cancer in the National Cancer Data Base. Anticancer Research, 2018, 38, 3175-3179.	0.5	7
108	Clinical benefit of treatment for metastatic renal cell cancer at high volume facilities. Annals of Translational Medicine, 2018, 6, S90-S90.	0.7	0

#	Article	IF	CITATIONS
109	Trends in the use of implantable accelerated partial breast irradiation for ductal carcinoma in situ : Implications of the recent amendments to the American Society for Radiation Oncology consensus guidelines. Brachytherapy, 2017, 16, 402-408.	0.2	2
110	Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma. Journal of Neuro-Oncology, 2017, 133, 369-375.	1.4	48
111	Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nature Reviews Urology, 2017, 14, 549-563.	1.9	88
112	Early outcomes of uveal melanoma treated with intraoperative ultrasound guided brachytherapy using custom built plaques. Practical Radiation Oncology, 2017, 7, e275-e282.	1.1	18
113	Histopathologic Analysis of Transvitreal Fine Needle Aspiration Biopsy Needle Tracts for Uveal Melanoma. American Journal of Ophthalmology, 2017, 174, 9-16.	1.7	20
114	GBM skin metastasis: a case report and review of the literature. CNS Oncology, 2017, 6, 203-209.	1.2	16
115	Radiation therapy utilization and outcomes for older women with breast cancer: Impact of molecular subtype and tumor grade. Breast, 2017, 35, 34-41.	0.9	15
116	Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma. Journal of Neuro-Oncology, 2017, 135, 173-181.	1.4	43
117	Consensus guidelines for postoperative stereotactic body radiation therapy for spinal metastases: results of an international survey. Journal of Neurosurgery: Spine, 2017, 26, 299-306.	0.9	88
118	Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base. Gynecologic Oncology, 2017, 144, 28-33.	0.6	35
119	Trends in cardiac mortality in women with ductal carcinoma in situ. Breast Cancer Research and Treatment, 2017, 161, 345-351.	1.1	7
120	Chemotherapy Versus Chemoradiation for Node-Positive Bladder Cancer: Practice Patterns and Outcomes from the National Cancer Data Base. Bladder Cancer, 2017, 3, 283-291.	0.2	23
121	The utility of positron emission tomography/computed tomography in target delineation for stereotactic body radiotherapy for liver metastasis from primary gastric cancer: an illustrative case report and literature review. Journal of Gastrointestinal Oncology, 2017, 8, E39-E42.	0.6	5
122	Stereotactic body radiation therapy for prostate cancer—a review. Chinese Clinical Oncology, 2017, 6, S10-S10.	0.4	20
123	Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases. Chinese Clinical Oncology, 2017, 6, S17-S17.	0.4	16
124	Radical Cystectomy Versus Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics. , 2017, 37, 5603-5608.		24
125	Risk for pulmonary late effects in childhood Hodgkin lymphoma survivors Journal of Clinical Oncology, 2017, 35, 112-112.	0.8	0
126	Clinical outcomes, toxicity, and cosmesis in breast cancer patients with close skin spacing treated with accelerated partial breast irradiation (APBI) using multi-lumen/catheter applicators. Journal of Contemporary Brachytherapy, 2016, 6, 497-504.	0.4	4

#	Article	IF	CITATIONS
127	Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis. Radiotherapy and Oncology, 2016, 120, 150-155.	0.3	9
128	Accelerated partial breast irradiation: advances and controversies. Chinese Journal of Cancer, 2016, 35, 31.	4.9	12
129	Chemotherapy in non-small cell lung cancer: opportunities for advancement. Chinese Journal of Cancer, 2016, 35, 56.	4.9	4
130	Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Expert Review of Anticancer Therapy, 2016, 16, 523-530.	1.1	28
131	Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncology, 2016, 12, 637-645.	1.1	56
132	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro-Oncology, 2016, 18, 1137-1145.	0.6	126
133	Treatment outcome and prognostic factors in male patients with stage IV breast cancer: A population-based study Journal of Clinical Oncology, 2016, 34, 572-572.	0.8	4
134	Combined radiotherapy and immunotherapy–a new promising treatment approach in oncology. Journal of Radiation Oncology, 2015, 4, 319-319.	0.7	1
135	The role of combined radiation and immunotherapy in breast cancer treatment. Journal of Radiation Oncology, 2015, 4, 347-354.	0.7	5
136	Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. Journal of Radiation Oncology, 2015, 4, 365-375.	0.7	1
137	Dosimetric considerations and early clinical experience of accelerated partial breast irradiation using multi-lumen applicators in the setting of breast augmentation. Journal of Contemporary Brachytherapy, 2015, 6, 423-429.	0.4	3
138	Long-term outcome of a phase II trial using immunomodulatory in situ gene therapy in combination with intensity-modulated radiotherapy with or without hormonal therapy in the treatment of prostate cancer. Journal of Radiation Oncology, 2015, 4, 377-386.	0.7	3
139	Radiotherapy and the abscopal effect: insight from the past, present, and future. Journal of Radiation Oncology, 2015, 4, 321-330.	0.7	2
140	The use of modern imaging technologies in radiation therapy of cervical cancer. Journal of Radiation Oncology, 2015, 4, 1-10.	0.7	3
141	Long-term outcome of accelerated partial breast irradiation using a multilumen balloon applicator in a patient with existing breast implants. Brachytherapy, 2015, 14, 289-292.	0.2	4
142	Comparison of supine and prone craniospinal irradiation in children with medulloblastoma. Practical Radiation Oncology, 2015, 5, 93-98.	1.1	8
143	ACR Appropriateness Criteria [®] Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis. Journal of Palliative Medicine, 2015, 18, 573-584.	0.6	40
144	Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma. Radiotherapy and Oncology, 2015, 114, 224-229.	0.3	57

#	Article	IF	CITATIONS
145	The development of stereotactic body radiotherapy in the past decade: a global perspective. Future Oncology, 2015, 11, 2721-2733.	1.1	8
146	Reconstruction of four-dimensional computed tomography lung images by applying spatial and temporal anatomical constraints using a Bayesian model. Journal of Medical Imaging, 2015, 2, 024004.	0.8	3
147	Liver regeneration following repeat SBRT. Journal of Gastrointestinal Oncology, 2015, 6, E2-6.	0.6	5
148	Stereotactic body radiotherapy (SBRT)/stereotactic ablative body radiotherapy (SABR) for "radioresistant―renal cell carcinoma (RCC). Journal of Radiation Oncology, 2014, 3, 339-346.	0.7	7
149	A comparison of traditional vs. response-based involved-field radiotherapy on clinical target volume and organs at risk for pediatric rapid early responders with high-risk Hodgkin lymphoma. Journal of Radiation Oncology, 2014, 3, 99-104.	0.7	1
150	Patients with bilateral breast ductal carcinoma in situ treated with accelerated partial breast irradiation—initial experience. Journal of Radiation Oncology, 2014, 3, 293-298.	0.7	1
151	Sarcoidosis Presenting As Metastatic Lymphadenopathy in Breast Cancer. Clinical Breast Cancer, 2014, 14, e107-e110.	1.1	10
152	The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far?. Journal of Gastrointestinal Oncology, 2014, 5, 236-46.	0.6	27
153	Nonadherence of adjuvant radiation in NSCLC patients with N2 disease after lobectomy Journal of Clinical Oncology, 2014, 32, 7536-7536.	0.8	0
154	External radiation treatment of malignant liver disease: a critical review. Journal of Radiation Oncology, 2013, 2, 249-262.	0.7	0
155	Schedule-dependent interactions between perifosine and radiotherapy in prostate cancer. Journal of Radiation Oncology, 2013, 2, 209-216.	0.7	1
156	Whole lung irradiation in pediatric patients using helical tomotherapy to minimize cardiac, breast, and thyroid dose. Journal of Radiation Oncology, 2013, 2, 49-53.	0.7	3
157	Helical Mode Lung 4D-CT Reconstruction Using Bayesian Model. Lecture Notes in Computer Science, 2013, 16, 33-40.	1.0	3
158	Early recurrence in glioblastoma Journal of Clinical Oncology, 2013, 31, e13032-e13032.	0.8	0
159	Hypofractionated radiotherapy for prostate cancer. Lancet Oncology, The, 2012, 13, 5-6.	5.1	6
160	Preservation of adrenal function after successful stereotactic body radiation therapy of metastatic renal cell carcinoma involving the remaining contralateral adrenal gland. Practical Radiation Oncology, 2012, 2, 270-273.	1.1	7
161	A review of stereotactic body radiation therapy (SBRT) from the molecular radiobiology perspective. Journal of Radiation Oncology, 2012, 1, 311-316.	0.7	7
162	Stereotactic body radiotherapy for the treatment of spinal metastases. Journal of Radiation Oncology, 2012, 1, 255-265.	0.7	10

#	Article	IF	CITATIONS
163	Serum testosterone level after intensity-modulated radiotherapy in low-risk prostate cancer patients: does testicular dose correlate with testosterone level?. Journal of Radiation Oncology, 2012, 1, 173-177.	0.7	6
164	Clinical outcomes of patients with malignant lung lesions treated with stereotactic body radiation therapy (SBRT) in five fractions. Journal of Radiation Oncology, 2012, 1, 57-63.	0.7	0
165	Diagnosis and treatment options including stereotactic body radiation therapy (SBRT) for adrenal metastases. Journal of Radiation Oncology, 2012, 1, 43-48.	0.7	4
166	Clinical outcomes of patients with tumor bed-to-skin distance (TBS) ≤ mm treated with accelerated partial breast irradiation (APBI) using multilumen catheter Journal of Clinical Oncology, 2012, 30, 182-182.	0.8	0
167	Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. Discovery Medicine, 2010, 10, 255-62.	0.5	15
168	Versatility of the Novalis System to Deliver Image-Guided Stereotactic Body Radiation Therapy (SBRT) for Various Anatomical Sites. Technology in Cancer Research and Treatment, 2007, 6, 347-354.	0.8	62
169	Rectal wall sparing by dosimetric effect of rectal balloon used during Intensity-Modulated Radiation Therapy (IMRT) for prostate cancer. Medical Dosimetry, 2005, 30, 25-30.	0.4	55
170	Intensity Modulated Radiation Therapy (IMRT) in the Management of Prostate Cancer. Cancer Investigation, 2004, 22, 913-924.	0.6	15
171	Predictors of Extracapsular Extension and Its Radial Distance in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2003, 9, 454-460.	1.0	35
172	The Use of Rectal Balloon During the Delivery of Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer. Cancer Journal (Sudbury, Mass), 2002, 8, 476-483.	1.0	75
173	The Baylor College of Medicine experience with gold seed implantation. , 1997, 13, 406-418.		27